Literature DB >> 2560420

Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).

G M Eliopoulos1, K Klimm, M J Ferraro, G A Jacoby, R C Moellering.   

Abstract

Combination with tazobactam substantially enhanced the activity of piperacillin against routine isolates of staphylococci, various Enterobacteriaceae, Acinetobacter anitratus, and Bacteroides fragilis. Tazobactam enhanced the activity of piperacillin more than fourfold against Pseudomonas aeruginosa spp. harboring eight of 12 plasmid-mediated beta-lactamases.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2560420     DOI： 10.1016/0732-8893(89)90082-5

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  11 in total

1.  Cross-Canada survey of resistance of 2747 aerobic blood culture isolates to piperacillin/tazobactam and other antibiotics.

Authors:  K R Forward; P A Franks; D E Low; R Rennie; A E Simor
Journal:  Can J Infect Dis       Date:  1998-01

2.  Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.

Authors:  D J Occhipinti; S L Pendland; L L Schoonover; E B Rypins; L H Danziger; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

3.  Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.

Authors:  M Pfaller; A Barry; P Fuchs; E Gerlach; D Hardy; J McLaughlin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-03       Impact factor: 3.267

Review 4.  Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications.

Authors:  R Sutherland
Journal:  Infection       Date:  1995 Jul-Aug       Impact factor: 3.553

5.  Piperacillin/tazobactam in complicated urinary tract infections.

Authors:  P Nowé
Journal:  Intensive Care Med       Date:  1994-07       Impact factor: 17.440

6.  Metallo-beta-lactamase-producing gram-negative bacilli: laboratory-based surveillance in cooperation with 13 clinical laboratories in the Kinki region of Japan.

Authors:  Hisaaki Nishio; Masaru Komatsu; Naohiro Shibata; Kouichi Shimakawa; Noriyuki Sueyoshi; Toshiro Ura; Kaori Satoh; Masahiro Toyokawa; Tatsuya Nakamura; Yasunao Wada; Tamaki Orita; Tomomi Kofuku; Katsutoshi Yamasaki; Masako Sakamoto; Shohiro Kinoshita; Masanori Aihara; Yoshichika Arakawa
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

7.  Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam.

Authors:  M A Pfaller; A L Barry; P C Fuchs; E H Gerlach; D J Hardy; J C McLaughlin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

8.  In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria.

Authors:  G J Malanoski; L Collins; C Wennersten; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

9.  Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients.

Authors:  A Micozzi; M Nucci; M Venditti; G Gentile; C Girmenia; G Meloni; P Martino
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-01       Impact factor: 3.267

10.  Susceptibility of Haemophilus influenzae to piperacillin-tazobactam combinations: interpretive criteria and quality control limits for standardized tests.

Authors:  A L Barry; P C Fuchs; J H Jorgensen; F C Tenover; S D Allen; D J Hardy; J C McLaughlin
Journal:  J Clin Microbiol       Date:  1993-03       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.